2015
DOI: 10.18632/oncotarget.5272
|View full text |Cite
|
Sign up to set email alerts
|

Silencing NKD2 by promoter region hypermethylation promotes gastric cancer invasion and metastasis by up-regulating SOX18 in human gastric cancer

Abstract: Naked cuticle homolog2 (NKD2) is located in chromosome 5p15.3, which is frequently loss of heterozygosity in human colorectal and gastric cancers. In order to understand the mechanism of NKD2 in gastric cancer development, 6 gastric cancer cell lines and 196 cases of human primary gastric cancer samples were involved. Methylation specific PCR (MSP), gene expression array, flow cytometry, transwell assay and xenograft mice model were employed in this study. The expression of NKD1 and NKD2 was silenced by promot… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
40
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 27 publications
(40 citation statements)
references
References 35 publications
0
40
0
Order By: Relevance
“…[12][13][14][15][16] Decreased expression of NKD1 probably caused by its promoter hypermethylation has been reported in human cancer including primary hepatocellular carcinoma, small lung adenocarcinoma, breast invasive ductal carcinoma, and gastric cancer. [12][13][14][15][16] However, a few studies also observed increased expression of NKD1 in human hepatoblastomas and colon tumors. 30,31 These results indicated that NKD1 played different roles in different types of human cancers.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…[12][13][14][15][16] Decreased expression of NKD1 probably caused by its promoter hypermethylation has been reported in human cancer including primary hepatocellular carcinoma, small lung adenocarcinoma, breast invasive ductal carcinoma, and gastric cancer. [12][13][14][15][16] However, a few studies also observed increased expression of NKD1 in human hepatoblastomas and colon tumors. 30,31 These results indicated that NKD1 played different roles in different types of human cancers.…”
Section: Discussionmentioning
confidence: 99%
“…11 Reduced NKD1 expression has been increasingly demonstrated in several solid tumors. [12][13][14][15][16] However, the status of NKD1 expression and its clinical implication in AML remain largely elusive. Therefore, we focused on the NKD1 expression and its clinical significance in de novo patients with AML.…”
Section: Introductionmentioning
confidence: 99%
“…A high proportion of deaths related to GC is caused by tumor metastasis, postoperative recurrence, and delayed detection of advanced stage disease [2, 3]. During the process of metastasis and invasion, tumor cells are able to induce a series of changes characterized by diffusible growth factors and cytokines, components of the extracellular matrix, fibroblasts, and myofibroblasts (also called cancer-associated fibroblasts [CAFs]), comprising the tumor microenvironment [4].…”
Section: Introductionmentioning
confidence: 99%
“…Research by Jia et al (42) was carried out on material from 196 cases of stomach cancer and the 6 human stomach cancer cell lines SGC7901, MGC803, BGC823, AGS, N87 and MKN45. In these experiments, the authors determined the level of methylation of the naked cuticle homolog (NKD) -1 and -2 gene promoters, SOX18 direct inhibitors, on the aforementioned material.…”
Section: Stomach and Liver Cancermentioning
confidence: 99%
“…In these experiments, the authors determined the level of methylation of the naked cuticle homolog (NKD) -1 and -2 gene promoters, SOX18 direct inhibitors, on the aforementioned material. It turned out that the methylation of the NKD1 gene is influenced, among others, by the ability of the cancer cells to migrate and create metastases (42). In turn, the active NKD2 protein effectively inhibits cell proliferation and colony formation, and it also stops the cell cycle at the G2/M control point.…”
Section: Stomach and Liver Cancermentioning
confidence: 99%